DIVISLAB
Divi'S Laboratories Limited
Each stock's 10,000-path forecast, rendered as light.
Divi'S Laboratories Limited (DIVISLAB) Stock Analysis & Case Study
Is DIVISLAB a good buy? The data-driven verdict.
Divi'S Laboratories Limited (DIVISLAB) trades at ₹8,275,on the numbers it mixed signals, a Downstox Snapshot Score of 53/100.
On the numbers, Divi'S Laboratories Limited (DIVISLAB) mixed signals, a Downstox Snapshot Score of 53/100, weighing expensive at 73.7× earnings, ROE of 16.5%, a 65% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
DIVISLAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How DIVISLAB ranks against the 2,373 companies in our screener
- DIVISLAB's market cap of 2.20L Cr ranks in the top 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DIVISLAB's book value of ₹631 ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DIVISLAB's promoter holding of 51.9% ranks in the 35th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DIVISLAB's 3-year profit (PAT) growth of 13.0% ranks in the 46th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DIVISLAB's 3-year revenue growth of 11.0% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a debt-to-equity ratio figure for DIVISLAB, as of 9 Aug 2026, so it is not ranked here.
Is DIVISLAB overvalued? DIVISLAB P/E vs its Pharma
DIVISLAB's P/E of 73.7× sits above the Pharma peer median of 33.0×, so on earnings it screens richer than peers, while its 0.36% dividend yield is below the peer median of 0.68%.
DIVISLAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of DIVISLAB history (20%/yr drift, 26%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| DIVISLAB 2027 | ₹6,547 | ₹9,119 | ₹12,702 | +10% |
| DIVISLAB 2028 | ₹6,301 | ₹10,050 | ₹16,029 | +21% |
| DIVISLAB 2029 | ₹6,324 | ₹11,075 | ₹19,395 | +34% |
| DIVISLAB 2030 | ₹6,324 | ₹12,205 | ₹23,555 | +47% |
| DIVISLAB 2031 | ₹6,448 | ₹13,451 | ₹28,060 | +63% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability DIVISLAB goes up, or doubles?
The bull case for DIVISLAB
- DIVISLAB's return on equity of 16.5% ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DIVISLAB's return on capital employed of 22.0% ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 65% chance the price is higher in a year, with a median target of ₹9,119 (+10%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹19,395.
The bear case & risks
- DIVISLAB's P/E of 73.7x is lower than 16% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 13.1× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹6,324.
DIVISLAB volatility & expected range, how bumpy is the ride?
Over the last 9.8 years DIVISLAB compounded at 20%/year with annualized volatility of 26%. That volatility implies a 1-year 80% range of ₹6,547-₹12,702, the honest backbone behind any single price target.
DIVISLAB price forecast, the full 60-month probability fan
DIVISLAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds DIVISLAB hits common targets within the simulated horizon?
Full multi-horizon detail on the DIVISLAB price target & forecast page.
DIVISLAB Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. DIVISLAB scores 6/8, mixed financial health.
DIVISLAB MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy DIVISLAB with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 23.91% | 4.2× |
| Zerodha | 23.40% | 4.3× |
| Groww | 23.38% | 4.3× |
| Dhan | 22.00% | 4.5× |
| Kotak NeoCHEAPEST | 20.41% | 4.9× |
| Paytm Money | 20.46% | 4.9× |
| Pocketful | 26.86% | 3.7× |
| Fyers | 27.78% | 3.6× |
| Anand Rathi | 27.40% | 3.6× |
| Bajaj Broking | 23.00% | 4.3× |
| Share India | 27.43% | 3.6× |
Compare every broker on the DIVISLAB MTF page.
DIVISLAB vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| DIVISLAB (this stock) | 73.7× | 0.36% | ₹2.20L Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
| BIOCON | 95.5× | 0.12% | ₹69,482 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About Divi'S Laboratories Limited: sector, index & market-cap context
Divi'S Laboratories Limited (DIVISLAB) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 500 index, with a market capitalisation of ₹2.20L Cr. See more stocks on our screener.
How the DIVISLAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Divi'S Laboratories Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
DIVISLAB analysis, FAQs
Is Divi'S Laboratories Limited (DIVISLAB) a good buy?
On the numbers, Divi'S Laboratories Limited (DIVISLAB) mixed signals, a Downstox Snapshot Score of 53/100, weighing expensive at 73.7× earnings, ROE of 16.5%, a 65% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is DIVISLAB overvalued or undervalued?
DIVISLAB trades at 73.7× earnings versus a peer median of 33.0×, so it screens richer than its Pharma peers.
What is the DIVISLAB share price target for 2031?
DIVISLAB's probability-weighted 2031 median target is ₹13,451, with an 80% range of ₹6,448-₹28,060 (10,000-path Monte-Carlo).
What is the probability DIVISLAB doubles in 5 years?
The modelled probability of DIVISLAB reaching ₹16,550 (2×) within 5 years is 35%.
What is the bull case for DIVISLAB?
DIVISLAB's return on equity of 16.5% ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. DIVISLAB's return on capital employed of 22.0% ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 65% chance the price is higher in a year, with a median target of ₹9,119 (+10%).
What are the risks in DIVISLAB?
DIVISLAB's P/E of 73.7x is lower than 16% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 13.1× price-to-book means most of the value is intangible/expectations, not assets on the books.